Horizon Blue Cross Blue Shield, New Jersey’s largest health insurance plan, to reimburse for GPS CancerTM comprehensive molecular test in investigational cancer studies for certain lung, breast and colon cancers
The supercomputing genomics engine, a decade in the making, has successfully completed analyses of more than 21,000 cancer tissue samples analyzed for whole genome, whole exome and RNA from more than 7,000 unique patients with multiple tumor types—and with the world’s largest database of human cancer whole genomes—enabled the discovery of novel neoepitopes in cancer tissue for the development of neoepitope antibodies and vaccines in the war against cancer
Health systems ordering GPS Cancer, including Cancer Institute of New Jersey, John Theurer Cancer Center and University of Pennsylvania, will also track cost and outcomes through COTA, a leading oncology analytics software platform
CULVER CITY, Calif. & NEWARK, N.J.–(BUSINESS WIRE)–Oct. 26, 2016–
NantHealth, Inc. (Nasdaq: NH):
|
WHAT: |
Panel discussion and press conference with Dr. Patrick Soon-Shiong, Founder and CEO of NantHealth, Inc. (Nasdaq: NH), a leading next-generation, evidence-based, personalized healthcare company, and esteemed leadership of Horizon Blue Cross Blue Shield of New Jersey who will cover GPS Cancer tests to advance molecular science for its members enrolled in investigational studies for key cancer types—non-small cell lung cancer, breast cancer, colon cancer, and cancer of unknown primary—across leading health systems in the mid-Atlantic. These institutions, who will also participate in the panel discussion, include the Hospital of University of Pennsylvania (HUP), Cancer Institute of New Jersey, Hackensack Medical Center, Meridian Hospital and Regional Cancer Care Associates LLC (RCCA). They will also utilize COTA, Inc.’s analytics solution to monitor and track differences in clinical outcomes and cost-analysis throughout these investigational efforts. Representing COTA, Inc. on the panel will be Kelly Choi, MD, and Stuart Goldberg, MD. The key insights to be shared by Dr. Soon-Shiong and the panel: |
||
|
— Advancements in immunotherapy enabled by GPS Cancer to advance molecular science, which provide oncologists with unprecedented insights to help identify personalized, cost-effective therapy strategies before treatment begins. |
|||
|
— How the studies can further the development and understanding of novel neoepitope antibodies, and their role in finally achieving low toxicity, targeted cancer therapy—with the ultimate hope of cancer antibodies or vaccines. |
|||
|
— The role of machine learning in the complex understanding of the cancer genome and how NantWork’s Medical Reasoning Engine provides real-time predictive modeling and clinical outcomes that can continually improve physicians’ ability to make more effective care decisions. |
|||
|
— How these initiatives can help address the new requirements of the Centers for Medicare and Medicaid Service (CMS) Oncology Care Model’s new targets for better care, smarter spending and healthier populations. |
|||
|
WHO: |
— Dr. Patrick Soon-Shiong, Founder and CEO, NantWorks and leader of Cancer MoonShot2020 |
||
|
— Allen Karp, SVP, Healthcare Management at Horizon Blue Cross Blue Shield New Jersey |
|||
|
— Mary Ann Christopher, Chief of Clinical Operations and Transformation at Horizon Blue Cross Blue Shield New Jersey |
|||
|
— Dr. Andrew Pecora, CIO, Hackensack University Medical Center |
|||
|
— Dr. Shridar Ganesan, Rutgers Cancer Institute of New Jersey |
|||
|
— Dr. Stuart Goldberg, COTA |
|||
|
— Kyle Stern, Managing Partner, HealthScape Advisors |
|||
|
WHEN: |
Thursday, October 27, 2016, 2:00-3:00 p.m. ET | ||
|
WHERE: |
Horizon Blue Cross Blue Shield New Jersey |
||
| 3 Penn Plaza | |||
| Newark, New Jersey | |||
Members of the media must RSVP to Kevin McArdle by noon, Oct. 26.
Cautionary Note Concerning Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding the capabilities and anticipated utility of our GPS Cancer, including predicting patient response and resistance to therapeutics, enabling diagnoses by physicians and accelerating efforts to bring novel combinations of therapeutic agents to cancer patients, as well as our contribution to the Cancer 2020 initiative. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results. Factors that may cause future results to differ materially from management’s current expectations include, among other things, that GPS Cancer may not perform as anticipated, that sufficient physicians may not adopt GPS Cancer to assist their diagnoses or that healthcare payers may not provide reimbursement for GPS Cancer as expected. Our business is subject to numerous additional risks and uncertainties, including, among others, risks relating to market acceptance of our products; our ability to successfully launch new products and applications; competition; our sales, marketing and distribution capabilities; our planned sales, marketing, and research and development activities; unanticipated increases in costs or expenses; and risks associated with international operations. Information on these and additional risks, uncertainties, and other information affecting our business and operating results can be found in our existing and future filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements except as may be required by law.
About NantHealth, Inc.
NantHealth, Inc., a member of the NantWorks ecosystem of companies, is a next-generation, evidence-based, personalized healthcare company enabling improved patient outcomes and more effective treatment decisions for critical illnesses. NantHealth‘s unique systems-based approach to personalized healthcare applies novel diagnostics tailored to the specific molecular profiles of patient tissues and integrates this molecular data in a clinical setting with large-scale, real-time biometric signal and phenotypic data to track patient outcomes and deliver precision medicine. For nearly a decade, NantHealth has developed an adaptive learning system, CLINICS, which includes its unique software, middleware and hardware systems infrastructure that collects, indexes, analyzes and interprets billions of molecular, clinical, operational and financial data points derived from novel and traditional sources, continuously improves decision-making and further optimizes our clinical pathways and decision algorithms over time. For more information please visit www.nanthealth.com and follow Dr. Soon-Shiong on Twitter @DrPatSoonShiong.
About GPS Cancer™
GPS Cancer™ is a unique, molecular profile analysis available through NantHealth. GPS Cancer integrates whole genome (DNA) sequencing, whole transcriptome (RNA) sequencing, and quantitative proteomics through mass spectrometry, providing oncologists with a comprehensive molecular profile of a patient’s cancer and an assessment of protein pathway function to inform personalized treatment strategies. GPS Cancer scanning is conducted in CLIA-certified and CAP-accredited laboratories, and is a key enabler for Cancer MoonShot 2020, the world’s most comprehensive cancer collaborative initiative seeking to accelerate the potential of combination immunotherapy as the next generation standard of care in cancer patients. For more information, visit www.gpscancer.com and www.cancermoonshot2020.org.
About Horizon Blue Cross Blue Shield of New Jersey Horizon
Blue Cross Blue Shield of New Jersey, the state’s oldest and largest health insurer is a tax-paying, not-for-profit health service corporation, providing a wide array of medical, dental, and prescription insurance products and services. Horizon BCBSNJ is leading the transformation of health care in New Jersey by working with doctors and hospitals to deliver innovative, patient-centered programs that reward the quality, not quantity, of care patients receive. Learn more at www.HorizonBlue.com. Horizon BCBSNJ is an independent licensee of the Blue Cross and Blue Shield Association serving more than 3.8 million members.
About COTA, Inc.
COTA is the health care informatics and precision analytics company that builds research-grade, real-world data to exponentially improve outcomes, reduce cost and ensure the right care for the right patient every time. The patented COTA Nodal Address System (CNA) is the first and only digital classification system that transforms prognostically significant variables into a digital code — precisely categorizing patient factors, their diseases and intended therapies to measure treatment outcomes, identify variances in care and enable quality benchmarking, research, discovery and the transition to value-based medicine. For more information, please visit www.oncota.com. COTA – Best Care Made Clear.™